GT Biopharma Starts Phase 1 B7-H3 TriKE Trial, Holds $9M Cash
GT Biopharma dosed a patient May 14, 2026 in a Phase 1 trial of GTB-5550, a B7-H3-targeted NK cell engager administered subcutaneously in advanced prostate, ovarian and pancreatic cancers. It held $9 million at March 31, 2026, funding operations through Q4 2026 and expects Phase 1 data in 2H 2026.
1. Phase 1 Trial Initiation
On May 14, 2026 GT Biopharma dosed the first patient in its Phase 1 dose-escalation basket trial evaluating GTB-5550, a tri-specific natural killer cell engager targeting B7-H3 in solid tumors.
2. Subcutaneous TriKE Platform
GTB-5550 is a second-generation TriKE composed of camelid anti-CD16, IL-15 and anti-B7-H3 arms, designed for subcutaneous administration to enhance patient convenience and NK cell activation compared to continuous infusions.
3. Targeted Cancer Indications
The trial prioritizes advanced prostate, ovarian and pancreatic cancer patients who have failed prior therapies, reflecting B7-H3’s overexpression in these and other lethal solid tumors with high unmet medical needs.
4. Financial Runway and Milestones
As of March 31, 2026 GT Biopharma held approximately $9 million in cash, sufficient to fund operations through Q4 2026, with initial Phase 1 data expected in the second half of 2026.